# RNA Therapeutics Market Size, Share, Trends & Forecast 2026–2035

> The Global RNA Therapeutics market was valued at USD 11,864.3 Mn in 2025 and will reach USD 38,424.6 Mn by 2035 at a 12.47% CAGR, according to Vectomat Insights. mRNA leads modalities with a 45.9% share, North America holds 39.0% of revenue, and self-amplifying RNA is the fastest-growing modality at 18.6% a year.

- Publisher: Vectomat Insights
- Report code: VMI-1-1-28152
- Published: 2026-11-07
- Canonical URL: https://www.vectomatinsights.com/report/rna-therapeutics-market
- Base year 2025: USD 11,864.3 Mn
- Forecast 2035: USD 38,424.6 Mn
- CAGR 2026–2035: 12.47%

## Key insights

- The global RNA therapeutics market grows from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn by 2035, a 12.47% CAGR across the 2026–2035 forecast horizon.
- mRNA is the dominant modality at 45.9% of 2025 revenue (USD 5,440.4 Mn), carried by Comirnaty, Spikevax and the newer mNEXSPIKE and mRESVIA vaccines.
- Self-amplifying RNA is the fastest-growing modality at an 18.6% CAGR, lifting from USD 830.5 Mn in 2025 to USD 4,574.0 Mn by 2035 after Kostaive's EU approval in February 2025.
- Infectious disease vaccines lead applications at 37.9% of 2025 revenue (USD 4,490.9 Mn), though the segment dipped from USD 4,794.9 Mn in 2024 as US COVID-19 demand fell.
- Biopharmaceutical companies account for 60.0% of 2025 spend because sponsors keep RNA synthesis and LNP formulation in-house, while CROs/CDMOs grow fastest at 18.99% a year.
- North America holds 39.0% of global revenue (USD 4,627.1 Mn), with the United States alone at USD 3,701.7 Mn in 2025.
- Asia Pacific is the fastest-growing region; South Korea, at a 14.7% CAGR, is the fastest-growing highlighted country and reaches about USD 2,151.1 Mn by 2035.
- Consolidation is redrawing the competitive map: Novartis closed its roughly USD 12 Bn purchase of Avidity Biosciences in February 2026 and BioNTech absorbed CureVac in December 2025.
- Cardiometabolic disease is the next volume frontier, growing at 16.96% a year as Leqvio, Tryngolza and Redemplo move RNA drugs from rare disease into common chronic conditions.

## Figures

![RNA Therapeutics Market size — USD 11,864.3 Mn (2025) to USD 38,424.6 Mn (2035), 12.47% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-size-vmi.png) — The RNA therapeutics market more than triples from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn in 2035, a 12.47% CAGR. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market DROC — 4 drivers, 3 restraints, 4 opportunities, 2 challenges | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-droc-vmi.png) — siRNA expansion into common disease and platform M&A drive the market, while US vaccine policy and shrinking COVID-19 revenue hold back mRNA. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market share by region 2025 — North America leads at 39.0% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-regional-share-vmi.png) — North America holds 39.0% of 2025 revenue, ahead of Europe at 27.0% and Asia Pacific at 23.0%. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market segmentation — mRNA, infectious disease vaccines, LNPs and biopharma lead | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-segments-vmi.png) — mRNA (45.9%), infectious disease vaccines (37.9%), lipid nanoparticles (55.7%) and biopharmaceutical companies (60.0%) lead their dimensions in 2025. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market share by modality 2025 — mRNA 45.9%, siRNA 30.0% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-modality-share-vmi.png) — mRNA accounts for 45.9% of 2025 revenue and siRNA for 30.0%, with self-amplifying RNA the fastest-growing modality. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market share by end user 2025 — biopharma companies 60.0% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-end-user-share-vmi.png) — Biopharmaceutical companies account for 60.0% of 2025 spend, while CROs/CDMOs hold 26.0% and grow fastest. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market modality mix by region — mRNA leads in North America, Europe and Asia Pacific | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-regional-segments-vmi.png) — mRNA leads the modality mix in all three top regions, while Asia Pacific has the highest self-amplifying RNA share at 11.5%. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market competitive landscape — Moderna, BioNTech, Alnylam and Novartis lead | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-competitive-landscape-vmi.png) — Moderna, BioNTech, Alnylam Pharmaceuticals and Novartis combine commercial scale with platform breadth, while specialists and CDMOs fill focused niches. Source: Vectomat Insights, RNA Therapeutics Market Report.
![RNA Therapeutics Market at a glance — USD 11,864.3 Mn (2025), USD 38,424.6 Mn (2035), 12.47% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-key-numbers-vmi.png) — The market grows at a 12.47% CAGR to USD 38,424.6 Mn by 2035, led by mRNA, North America and a group of RNA specialists and vaccine makers. Source: Vectomat Insights, RNA Therapeutics Market Report.
![United States RNA Therapeutics Market — USD 3,701.7 Mn (2025) to USD 10,798.2 Mn (2035), 11.3% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-united-states-snapshot-vmi.png) — The United States RNA therapeutics market grows from USD 3,701.7 Mn in 2025 to USD 10,798.2 Mn in 2035 at a 11.3% CAGR. Source: Vectomat Insights, RNA Therapeutics Market Report.
![Germany RNA Therapeutics Market — USD 897.0 Mn (2025) to USD 2,524.1 Mn (2035), 10.9% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-germany-snapshot-vmi.png) — The Germany RNA therapeutics market grows from USD 897.0 Mn in 2025 to USD 2,524.1 Mn in 2035 at a 10.9% CAGR. Source: Vectomat Insights, RNA Therapeutics Market Report.
![South Korea RNA Therapeutics Market — USD 545.8 Mn (2025) to USD 2,151.1 Mn (2035), 14.7% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/rna-therapeutics-market/fe620c73b4def140/rna-therapeutics-market-south-korea-snapshot-vmi.png) — The South Korea RNA therapeutics market grows from USD 545.8 Mn in 2025 to USD 2,151.1 Mn in 2035 at a 14.7% CAGR. Source: Vectomat Insights, RNA Therapeutics Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 10,399.5 |
| 2024 | 10,990.2 |
| 2025 | 11,864.3 |

## Share by Modality (2025)

| Segment | Share | USD Mn |
|---|---|---|
| mRNA | 45.9% | 5,440.4 |
| siRNA | 30% | 3,559.3 |
| Antisense Oligonucleotides | 12.1% | 1,440.9 |
| Self-Amplifying RNA | 7% | 830.5 |
| Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities) | 5% | 593.2 |

## Share by Application (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Infectious Disease Vaccines | 37.9% | 4,490.9 |
| Oncology | 32% | 3,796.6 |
| Rare & Genetic Disease | 18% | 2,135.6 |
| Cardiometabolic Disease | 7.1% | 840.7 |
| Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine) | 5.1% | 600.5 |

## Share by Delivery Technology (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Lipid Nanoparticles | 55.7% | 6,609.2 |
| Viral Vectors | 20% | 2,372.9 |
| Polymer-Based Delivery | 12.3% | 1,458.6 |
| Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles) | 12% | 1,423.6 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Biopharmaceutical Companies | 60% | 7,118.6 |
| CROs/CDMOs | 26% | 3,084.7 |
| Academic & Research Institutes | 14% | 1,661.0 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 39% | 4,627.1 |
| Europe | 27% | 3,203.4 |
| Asia Pacific | 23% | 2,728.8 |
| Latin America | 5% | 590.2 |
| The Middle East | 3.1% | 362.6 |
| Africa | 3% | 352.2 |

## Key companies

- Alnylam Pharmaceuticals (U.S.): GalNAc-conjugated siRNA (Amvuttra, Onpattro, Givlaari, Oxlumo)
- Ionis Pharmaceuticals (U.S.): Antisense oligonucleotides for rare and cardiometabolic disease
- Arrowhead Pharmaceuticals (U.S.): TRiM-platform siRNA for cardiometabolic and pulmonary disease
- Novartis (Switzerland): siRNA (Leqvio) and antibody-oligonucleotide conjugates ('xRNA')
- Moderna (U.S.): mRNA vaccines (Spikevax, mNEXSPIKE, mRESVIA) and individualised cancer vaccines
- BioNTech (Germany): mRNA vaccines (Comirnaty with Pfizer) and mRNA oncology
- Pfizer (U.S.): mRNA COVID-19 vaccine Comirnaty (with BioNTech)
- Biogen (U.S.): Antisense therapy Spinraza (nusinersen) for spinal muscular atrophy
- Sarepta Therapeutics (U.S.): Neuromuscular gene therapy moving into siRNA via an Arrowhead licence
- CSL (Australia): Self-amplifying mRNA COVID-19 vaccine Kostaive (with Arcturus)
- Gennova Biopharmaceuticals (India): mRNA and self-amplifying mRNA vaccines
- Samsung Biologics (South Korea): Contract development and manufacturing, including mRNA
- Maravai LifeSciences (U.S.): mRNA raw materials through TriLink BioTechnologies (CleanCap capping)
- Aldevron (U.S.): Plasmid DNA, mRNA and Cas9 mRNA manufacturing (Danaher)
- Lonza (Switzerland): Contract manufacturing for mRNA and oligonucleotides

## FAQs

### What is the forecast CAGR of the RNA therapeutics market?

The global market grows at a 12.47% CAGR from 2026 to 2035, rising from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn. Rates differ widely by modality: self-amplifying RNA grows at 18.6%, antisense oligonucleotides at 15.66%, siRNA at 12.99% and mRNA at 10.22%. By end user, CROs and CDMOs grow fastest at 18.99% a year, according to Vectomat Insights.

### How is the RNA therapeutics market segmented in this report?

The report segments the market by modality (mRNA, siRNA, antisense oligonucleotides, self-amplifying RNA and others), by application (infectious disease vaccines, oncology, rare and genetic disease, cardiometabolic disease and others), by delivery technology (lipid nanoparticles, viral vectors, polymer-based delivery and others) and by end user. It also covers 6 regions and 35+ countries, analysing the Middle East separately from Africa, according to Vectomat Insights.

### Why is siRNA gaining share in RNA therapeutics?

siRNA drugs need only two to four injections a year, and GalNAc conjugation delivers them to the liver without a nanoparticle. That convenience made Alnylam's Amvuttra viable in ATTR cardiomyopathy and lets Leqvio and Redemplo compete in lipid disorders. siRNA holds 30.0% of 2025 revenue, worth USD 3,559.3 Mn, and its share rises to 31.4% by 2035 as these large indications mature, according to Vectomat Insights.

### How much does delivery technology matter in RNA therapeutics?

Delivery decides which tissues a drug can reach, so it shapes both pipelines and patent value. Lipid nanoparticles carry 55.7% of 2025 revenue, worth USD 6,609.2 Mn, and Moderna paid USD 2.25 Bn in March 2026 to settle LNP patent claims. GalNAc conjugates, peptides and other carriers grow fastest at 18.9% a year, while viral vectors lose share, according to Vectomat Insights.

### Which country is the fastest-growing in the RNA therapeutics market?

Among the countries highlighted in this report, South Korea grows fastest, at a 14.7% CAGR from USD 545.8 Mn in 2025 to about USD 2,151.1 Mn by 2035. Government backing through the KDCA mRNA vaccine programme and contract-manufacturing capacity at Samsung Biologics support that growth. The United States remains the largest single country at USD 3,701.7 Mn in 2025, according to Vectomat Insights.

### How does Vectomat Insights build the RNA therapeutics market estimate?

Analysts sized the market bottom-up from product revenue for approved mRNA, siRNA, antisense and self-amplifying RNA medicines, then checked it top-down against company-reported sales and pharmaceutical spending. Pipeline products enter the model at their expected launch year with phase-based approval odds. Segment, regional and country values are reconciled to the 2025 total of USD 11,864.3 Mn, according to Vectomat Insights.

### What role do CDMOs play in the RNA therapeutics market?

CROs and CDMOs supply synthesis, LNP formulation and fill-finish for developers that don't own plants. Their share of spend rises from 26.0% in 2025 to 45.7% by 2035, a growth rate of 18.99% a year, as new entrants and personalised cancer vaccines need flexible capacity. Samsung Biologics, Lonza and Aldevron are the main beneficiaries of that shift, according to Vectomat Insights.

Cite as: Vectomat Insights (2026). RNA Therapeutics Market Report. https://www.vectomatinsights.com/report/rna-therapeutics-market